Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas

Matteo Tantari, Fabio Barra, Stefano Di Domenico, Domenico Ferraioli, Valerio Gaetano Vellone, Franco De Cian, Simone Ferrero

Research output: Contribution to journalReview article

Abstract

Introduction: Uterine leiomyosarcomas (ULMS) account for 1% of all uterine malignancies and for 30% of all uterine sarcomas. The preoperative diagnosis of ULMS is challenging for the physicians, as the symptoms of these tumors are often vague and nonspecific. Moreover, as ULMS have an aggressive biologic behavior, affected women frequently have very poor prognosis. Areas covered: The aim of this review is to describe the current pharmacotherapy for ULMS, including the ongoing clinical trials. Expert opinion: Surgery is the standard treatment for patients with early-stage ULMS. In this setting, the role of adjuvant therapies is still unclear. In the case of advanced, persistent, or recurrent ULMS, chemotherapy is the standard care with the most frequently used drug being doxorubicin. As the outcomes for patients with the currently available conventional single or combined regimens are far from being satisfactory, new alternative and innovative medical compounds have or are being evaluated. Recently, pazopanib, and olaratumab, two innovative targeted drugs, have been approved by the Food and Drug Administration (FDA) for treating advanced soft-tissue sarcoma, including ULMS. However, further clinical investigations into new and innovation therapeutic options are warranted.

Original languageEnglish
Pages (from-to)713-723
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume20
Issue number6
DOIs
Publication statusPublished - Apr 13 2019

    Fingerprint

Keywords

  • doxorubicin
  • gemcitabine
  • Leiomyosarcomas
  • olaratumab
  • pazopanib
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this